Non Hodgkin Lymphoma Clinical Trial

PRO1160 for Advance Solid and Liquid Tumors (PRO1160-001)

Summary

Brief Summary:

This study will test the safety, including side effects, and determine the characteristics of a drug called PRO1160 in participants with solid tumors.

Participants will have solid tumor or liquid cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

This study will have two parts. Part A of the study will find out how much and how frequently PRO1160 should be given to participants. Part B will use the dose and schedule found in Part A to find out how safe PRO1160 is and if it works to treat the diseases under study.

Renal Cell Carcinoma (RCC) Drug: PRO1160 Phase 1/Phase 2 Nasopharyngeal Carcinoma (NPC) Non-Hodgkin Lymphoma (NHL)

View Full Description

Full Description

This is a Phase 1/2 study of PRO1160, a CD70 targeted antibody-drug conjugate, to evaluate the safety, tolerability, PK, and antitumor activity of PRO1160 in patients with selected locally advanced /or metastatic solid and liquid tumors, including renal cell carcinoma, nasopharyngeal carcinoma and non-hodgkin lymphoma. This study consists of 2 parts, Part A: Dose Escalation and Part B: Dose Expansion.

Part A may evaluate up to 7 dose levels of PRO1160 on Day 1 of a 21 day cycle by IV infusion.

Part B will be initiated at a dose level based on a comprehensive analysis of safety, tolerability, clinical PK, PD and activity data from Part A in up to 4 different cohorts of up to 20 patients per cohort.

Patients will continue to receive study treatment until the first instance of disease progression, unacceptable toxicity, investigator decision, consent withdrawal, study termination by the Sponsor, pregnancy, or death.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

-

Pathologically confirmed metastatic or unresectable solid malignancy including Renal Cell carcinoma, Nasopharyngeal carcinoma or Stage III or IV Non Hodgkin Lymphoma Relapsed or refractory disease following prior systemic therapies known to confer medical benefit willing to provide a tumor sample (archive tissue or fresh biopsy) ECOG performance status 0 or 1 measurable disease per RECIST v1.1 for RCC and NPC and per Lugano for NHL

Exclusion Criteria:

Prior treatment with anti-CD70 directed therapy other malignancy within 3 years active CNS metastases (treated, stable CNS metastases are allowed) uncontrolled Grade 3 or greater infection within 2 weeks positive for HBV, HCV or HIV use of a strong P450 CYP3A inhibitor within 14 days (dose escalation only) additional protocol defined inclusion/exclusion criteria may apply

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 1

Estimated Enrollment:

134

Study ID:

NCT05721222

Recruitment Status:

Not yet recruiting

Sponsor:

ProfoundBio US Co.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 5 Locations for this study

See Locations Near You

Karmanos Cancer Institute
Detroit Michigan, 48085, United States More Info
Elizabeth Heath, MD
Contact
[email protected]
Providence Cancer Institute
Portland Oregon, 97213, United States More Info
Brendan Curti, MD
Contact
503-215-5696
[email protected]
Sarah Canon Research Institute
Nashville Tennessee, 37203, United States More Info
Ben Garmezy, MD
Contact
713-444-7804
[email protected]
The University of Texas-MD Anderson Cncer Center
Houston Texas, 77030, United States
START Mountain Region
West Valley City Utah, 84119, United States More Info
Justin Call, MD
Contact
801-907-4750
[email protected]

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 1

Estimated Enrollment:

134

Study ID:

NCT05721222

Recruitment Status:

Not yet recruiting

Sponsor:


ProfoundBio US Co.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.